Education
About Us
Working with TipRanks
Follow Us
Conmed (CNMD)
NYSE:CNMD
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.82Last Year’s EPS
0.95Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic progress—strong adjusted results, meaningful growth in orthopedics, momentum in AirSeal/Buffalo Filter/BioBrace platforms, supply-chain improvements, and solid cash generation—against notable near-term headwinds: a sizeable GAAP earnings decline, tariff-driven margin pressure, and near-term dilution from the GI exit. Management provided constructive 2026 guidance but flagged increased SG&A and R&D investments and tariff impacts that compress near-term EPS. Overall the company appears to be executing a deliberate repositioning for longer-term, higher‑margin growth while accepting short-term earnings trade-offs.Company Guidance
Revenue Growth (Q4 and Full Year)
Total sales for Q4 were $373.2M, up 7.9% reported and 7.1% in constant currency. Full-year sales were $1.375B, up 5.2% reported and 5.1% in constant currency.
Adjusted EPS and Adjusted Net Income Expansion
Q4 adjusted EPS was $1.43, a 6.7% increase year-over-year; Q4 adjusted net income was $44.4M, up 6.2%. Full-year adjusted EPS was $4.59, up 10.1%, and full-year adjusted net income was $143.1M, up 10.1%.
Orthopedics Outperformance and Supply Chain Progress
Worldwide orthopedic sales grew 12.1% in Q4 and 5.5% for the full year (constant currency). U.S. ortho grew 6.6% in Q4 and international ortho grew 15.7% in Q4. Management reported meaningful supply-chain improvements with backorder value and SKUs on backorder at a three-year low.
AirSeal Traction and Long-Term Opportunity
AirSeal was used in ~1.6M procedures in 2025. Penetration in U.S. laparoscopy is only ~6%–7%, implying sizable white space. Management expects AirSeal to deliver high single-digit to low double-digit growth over the long term and noted a 10%–20% attachment rate to certain robotic platforms.
Buffalo Filter (Smoke Evacuation) Momentum
Company cites surgical smoke evacuation as a >$1B global market in early adoption; 20 U.S. states (≈51% of population) have enacted smoke-free OR laws. Launched PlumeSafe x5 in 2025 with product performance and noise improvements to strengthen market position.
BioBrace Clinical Adoption and Pipeline
BioBrace is used in >70 unique procedures and adoption is expanding (rotator cuff, foot & ankle). A 268-patient randomized controlled trial is on track to complete enrollment in 2026 with publication expected in 2027; AAOS guidelines (2025) recommend augmentation for rotator cuff repair.
Cash Generation, Leverage and Capital Allocation Flexibility
Operating cash flow for FY2025 was $170.7M (Q4 cash flow $46.3M). Cash balance $40.8M; long-term debt $834.2M and leverage 2.9x at year-end. Board approved $150M share repurchase authorization and suspended dividend (historically ~$25M annually), providing flexibility to redeploy capital.
2026 Financial Guidance and Margin Improvement Targets
Guidance for FY2026 revenue $1.345B–$1.375B (constant currency organic growth 4.5%–6%). Management targets adjusted gross margin net improvement of 50–100 bps for 2026 despite tariff headwinds, adjusted EPS guidance $4.30–$4.45, projected operating cash flow $145M–$155M, and adjusted EBITDA $255M–$265M.
CNMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CNMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 28, 2026 | $38.69 | $37.31 | -3.57% |
Nov 05, 2025 | $44.44 | $44.21 | -0.52% |
Jul 30, 2025 | $49.95 | $50.96 | +2.01% |
Apr 30, 2025 | $48.75 | $56.77 | +16.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Conmed (CNMD) report earnings?
Conmed (CNMD) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Conmed (CNMD) earnings time?
Conmed (CNMD) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CNMD EPS forecast?
CNMD EPS forecast for the fiscal quarter 2026 (Q1) is 0.82.